


SoonerCare Fast Facts

October 2022

TOTAL ENROLLMENT – OKLAHOMA SOONERCARE (MEDICAID)




Race is self-reported by members at the time of enrollment. The two or more race members have selected two or more races. Hispanic or Latino is an ethnicity, not a race. Hispanics or Latinos can be any race and are accounted for in the race category above. Pregnant women includes CHIP Prenatal.


645,192

590,921 80,179

Total Enrollment Trend



Percent of Federal Poverty Levels Totals



The "No Poverty Data" group consists of members with no poverty data and members enrolled with an aid category of U- DDSD State, R2 - OJA not Incarcerated, or R4 - OJA Incarcerated. These aid categories do not require poverty data or do not use the poverty data

SoonerCare Provides New Hepatitis C Virus Coverage

Oklahoma City, OK – The Oklahoma Health Care Authority launched an initiative to cure SoonerCare members who have been diagnosed with the hepatitis C virus (HCV). [Mavyret®](#) (glecaprevir/pibrentasvir) is now the preferred direct-acting antiviral (DAA) medication for HCV and is available without prior authorization (PA) for SoonerCare members. Removing the prior authorization allows for easier access to this medication to cure members with HCV.

Hepatitis contributes to nearly 14,000 U.S. deaths a year and fewer than one in three people infected with hepatitis C get treatment, according to a [report from the Centers for Disease Control and Prevention](#). The study found less than a third of people with health insurance get the hepatitis C medicines within a year of diagnosis

Approximately 4,200 SoonerCare members reported living with HCV in state fiscal year 2020. "This medication can be lifesaving for many SoonerCare members suffering from HCV. I am proud we can help these Oklahomans by providing direct-acting antiviral medications, which will improve their health outcomes," said Kevin Corbett, OHCA CEO and Secretary of Health and Mental Health.

Mavyret® is FDA approved to treat adult and pediatric patients 3 years of age and older. Mavyret® is the only DAA available without a PA and treats most types of hepatitis C, usually in 8 weeks. Some people may take longer to be cured, however, Mavyret has a 96-98% cure rate. Other HCV DAA medications are still covered by SoonerCare as they have been in the past, however, they continue to require prior authorization. SoonerCare members are encouraged to talk with their health care provider to see if they are at risk of getting hepatitis C and if they should be tested.

To learn more about SoonerCare coverage, visit mysooner.org.

Data was compiled by the Office of Data Governance and Analytics as of the report date and is subject to change. Numbers frequently change due to certifications occurring after the data is extracted and other factors. This report is based on data within the system prior to the report date. A majority of the data is a "point in time" representation of the specific report month and is not cumulative. Unless stated otherwise, CHILD is defined as an individual under the age of 21.